abcam

Product datasheet

Human IGF1R (IGF1 Receptor) knockout HeLa cell line ab264801

画像数 5

製品の概要

製品名	Human IGF1R (IGF1 Receptor) knockout HeLa cell line
Parental Cell Line	HeLa
Organism	Human
Mutation description	Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon 2 and 1 bp deletion in exon 2
Passage number	<20
Knockout validation	Sanger Sequencing, Western Blot (WB)
アプリケーション	**適用あり:** WB
Biosafety level	2
特記事項	**Recommended control:** Human wild-type HeLa cell line (**ab255448**). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1. **Cryopreservation cell medium:** Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose. **Culture medium:** DMEM (High Glucose) + 10% FBS **Initial handling guidelines:** Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. 1. Thaw the vial in 37°C water bath for approximately 1-2 minutes. 2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution. 3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of $2x10^4$ cells/cm^2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. 4. Incubate the culture at 37°C incubator with 5% CO_2. Cultures should be monitored daily. **Subculture guidelines:** All seeding densities should be based on cell counts gained by established methods. A guide seeding density of $2x10^4$ cells/cm^2 is recommended.

A partial media change 24 hours prior to subculture may be helpful to encourage growth, if required.
Cells should be passaged when they have achieved 80-90% confluence.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our **limited use license** and **patent pages**.

We will provide viable cells that proliferate on revival.

製品の特性

Number of cells	1 x 10^6 cells/vial, 1 mL
Adherent /Suspension	Adherent
Tissue	Cervix
Cell type	epithelial
Disease	Adenocarcinoma
Gender	Female
STR Analysis	Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10
Antibiotic resistance	Puromycin 1.00µg/ml
Mycoplasma free	Yes
保存方法	Shipped on Dry Ice. Store in liquid nitrogen.
バッファー	Constituents: 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether

ターゲット情報

機能

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be

activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.
When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

組織特異性

Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.

関連疾患

Insulin-like growth factor 1 resistance

配列類似性

Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Contains 4 fibronectin type-III domains.
Contains 1 protein kinase domain.

翻訳後修飾

Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner; Tyr-1165 is predominantly phosphorylated first, followed by phosphorylation of Tyr-1161 and Tyr-1166. While every single phosphorylation increases kinase activity, all three tyrosine residues in the kinase activation loop (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal activity. Can be autophosphorylated at additional tyrosine residues (in vitro). Autophosphorylated is followed by phosphorylation of juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278 by GSK-3beta restrains kinase activity and promotes cell surface expression, it requires a priming phosphorylation at Ser-1282. Dephosphorylated by PTPN1.
Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-48' and 'Lys-29' linkages, promoting receptor endocytosis and subsequent degradation by the proteasome. Ubiquitination is facilitated by pre-existing phosphorylation.
Sumoylated with SUMO1.
Controlled by regulated intramembrane proteolysis (RIP). Undergoes metalloprotease-dependent constitutive ectodomain shedding to produce a membrane-anchored 52 kDa C-Terminal fragment which is further processed by presenilin gamma-secretase to yield an intracellular 50 kDa fragment.

細胞内局在

Cell membrane.

アプリケーション

The Abpromise guarantee

Abpromise保証は、 次のテスト済みアプリケーションにおけるab264801の使用に適用されます

アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション	Abreviews	特記事項
WB		Use at an assay dependent concentration. Predicted molecular weight: 154 kDa.

画像



Western blot - Human IGF1R (IGF1 Receptor) knockout HeLa cell line (ab264801)

All lanes : Anti-IGF1 Receptor antibody [EPR23027-80] (**ab263907**) at 1/1000 dilution

Lane 1 : Wild-type HeLa cell lysate
Lane 2 : IGF1R knockout HeLa cell lysate

Lysates/proteins at 20 µg per lane.

Performed under reducing conditions.

Predicted band size: 154 kDa
Observed band size: 100 kDa

Lanes 1- 2: Merged signal (red and green). Green - **ab263907** observed at 100 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (**ab8245**) observed at 37 kDa.

ab263907 was shown to react with IGF1 Receptor in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab264801 (knockout cell lysate **ab256951**) was used. Wild-type HeLa and IGF1R knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. **ab263907** and Anti-GAPDH antibody [6C5] - Loading Control (**ab8245**) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (**ab216773**) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (**ab216776**) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.



Western blot - Human IGF1R (IGF1 Receptor) knockout HeLa cell line (ab264801)

All lanes : Anti-IGF1 Receptor antibody [EPR19322] (**ab182408**) at 1/1000 dilution

Lane 1 : Wild-type HeLa cell lysate
Lane 2 : IGF1R knockout HeLa cell lysate

Lysates/proteins at 20 µg per lane.

Performed under reducing conditions.

Predicted band size: 154 kDa
Observed band size: 100 kDa

Lanes 1- 2: Merged signal (red and green). Green - **ab182408** observed at 100 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (**ab8245**) observed at 37 kDa.

ab182408 was shown to react with IGF1 Receptor in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab264801 (knockout cell lysate **ab256951**) was used. Wild-type HeLa and IGF1R knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. **ab182408** and Anti-GAPDH antibody [6C5] - Loading Control (**ab8245**) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (**ab216773**) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (**ab216776**) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.



Sanger Sequencing - Human IGF1R (IGF1 Receptor) knockout HeLa cell line (ab264801)

Sequencing chromatogram displaying sequence edit in exon 2

Sanger Sequencing - Human IGF1R knockout HeLa cell line (ab264801)

Allele-1: 13 bp deletion in exon 2.

Sanger Sequencing - Human IGF1R knockout HeLa cell line (ab264801)

Allele-2: 1 bp deletion in exon 2.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit **https://www.abcam.co.jp/abpromise** or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors